The aim of the Evaluation-guided Development of New In Vitro Test Batteries (EDIT) multicentre programme is to establish and validate in vitro tests relevant to toxicokinetics and for organ-specific toxicity, to be incorporated into optimal test batteries for the estimation of human acute systemic toxicity. The scientific basis of EDIT is the good prediction of human acute toxicity obtained with three human cell line tests (R2 = 0.77), in the Multicentre Evaluation of In Vitro Cytotoxicity (MEIC) programme. However, the results from the MEIC study indicated that at least two other types of in vitro test ought to be added to the existing test battery to improve the prediction of human acute systemic toxicity — to determine key kinetic events (such as biotransformation and passage through biological barriers), and to predict crucial organ-specific mechanisms not covered by the tests in the MEIC battery. The EDIT programme will be a case-by-case project, but the establishment and validation of new tests will be carried through by a common, step-wise procedure. The Scientific Committee of the EDIT programme defines the need for a specific set of toxicity or toxicokinetic data. Laboratories are then invited to perform the defined tests in order to provide the “missing” data for the EDIT reference chemicals. The results obtained will be evaluated against the MEMO (the MEIC Monograph programme) database, i.e. against human acute systemic lethal and toxicity data. The aim of the round-table discussions at the 19th Scandinavian Society for Cell Toxicology (SSCT) workshop, held in Ringsted, Denmark on 6–9 September 2001, was to identify which tests are the most important for inclusion in the MEIC battery, i.e. which types of tests the EDIT programme should focus on. It was proposed that it is important to include in vitro methods for various kinetic events, such as biotransformation, absorption in the gut, passage across the blood–brain barrier, distribution volumes, protein binding, and renal clearance/accumulation. Models for target organ toxicity were also discussed. Because several of the outlier chemicals (paracetamol, digoxin, malathion, nicotine, paraquat, atropine and potassium cyanide) in the MEIC in vivo–in vitro evaluation have a neurotoxic potential, it was proposed that the development within the EDIT target organ programme should initially be focused on the nervous system.
EkwallB., ClemedsonC., EkwallB., RingP., & RomertL. (1999). EDIT: a new international multicentre programme to develop and evaluate batteries of in vitro tests for acute and chronic systemic toxicity. ATLA27, 339–349.
2.
EkwallB. (1998). MEIC evaluation of acute systemic toxicity. Part VI. Prediction of human toxicity by rodent LD50 values and results from 61 in vitro tests. ATLA26, 617–658.
3.
EkwallB., EkwallB., & SjöströmM. (2000). MEIC evaluation of acute systemic toxicity. Part VIII. Multivariate partial least squares evaluation, including the selection of a battery of cell line tests with a good prediction of human acute lethal peak blood concentrations for 50 chemicals. ATLA28, 201–234.
4.
EkwallB. (1999). Overview of the Final MEIC Results. II. The in vivo–in vitro evaluation, including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans. Toxicology in Vitro13, 665–673.
5.
ClemedsonC. (1996). MEIC evaluation of acute systemic toxicity. Part II. In vitro results from 68 toxicity assays used to test the first 30 reference chemicals and a comparative cytotoxicity analysis. ATLA24, 273–311.
6.
ClemedsonC. (1998). MEIC evaluation of acute systemic toxicity. Part III. In vitro results from 16 additional methods used to test the first 30 reference chemicals and a comparative cytotoxicity analysis. ATLA26, 91–129.
7.
ClemedsonC. (2000). MEIC evaluation of acute systemic toxicity. Part VII. Prediction of human toxicity by results from testing of the first 30 reference chemicals with 27 further in vitro assays. ATLA28, 161–200.
8.
EkwallB., & EkwallB. eds (1997). Time-related, High Survived and Lethal Blood Concentrations of Chemicals from Acute, Human Poisoning: MEIC Monographs 1–50.Stocksund, Sweden: CC Tox Consulting. Web site http://www.cctoxconsulting.a.se (Accessed 3.11.01).
9.
EkwallB., ClemedsonC., CrafoordB., EkwallB., HallanderS., WalumE., & BondessonI. (1998). MEIC evaluation of acute systemic toxicity. Part V. Rodent and human toxicity data for the 50 reference chemicals. ATLA26, 569–615.
10.
OECD (1992). OECD Guidelines for the Testing of Chemicals No. 420: Acute Oral Toxicity — Fixed Dose Method.Paris, France: Organisation for Economic Cooperation and Development.
11.
OECD (1996). OECD Guidelines for the Testing of Chemicals No. 423: Acute Oral Toxicity — Acute Toxic Class Method.Paris, France: Organisation for Economic Cooperation and Development.
12.
OECD (1998). OECD Guidelines for the Testing of Chemicals No. 425: Acute Oral Toxicity — Up-and-Down Procedure.Paris, France: Organisation for Economic Cooperation and Development.
DeJonghJ., Nordin-AnderssonM., PloegerB.A., & ForsbyA. (1999). Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. Toxicology and Applied Pharmacology158, 261–268.
16.
Anon. (2000). Report on the Biomed 2 EUROCYP: Integration of In Vitro Approaches to Predict Drug Metabolism and Interactions in Man in the Development of Pharmaceuticals: summary. Web site http://www.cordis.org/en/home.html (Accessed 3.11.01).
17.
OscarsonM., & Ingelman-SundbergM. (2000). Genetically modified cells to assess drug metabolism in vitro. In Approaches to High Throughput Toxicity Screening (ed. AtterwillC.K., PurcellW., & GoldfarbP.), pp. 136–167. London, UK: Taylor & Francis.
18.
KnasmüllerS., ParzefallW., SanyalR., EckerS., SchwabC., UhlM., Mersch-SundermannV., WilliamsonG., MietschG., LangerT., DarroudiF., & NatarajanA.T. (1998). Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutation Research462, 185–202.
19.
BD Biosciences (2001). Gentest Innovative In Vitro Drug Metabolism and Toxicology. Web site http://www.gentest.com (Accessed 20.10.01).
20.
CrespiC.L., GonzalezF.J., SteimelD.T., TurnerT.R., GelboinH.V., PenmanB.W., & LangenbachR. (1991). A metabolically competent human cell line expressing five cDNAs encoding procarcinogen activating enzymes: application to mutagenicity testing. Chemical Research in Toxicology4, 566–572.
21.
CrespiC.L., LangenbachR., & PenmanB.W. (1993). Human cell lines, derived from AHH-1 TK+/– human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology82, 89–104.
22.
BondessonI., EkwallB., HellbergS., RomertL., StenbergK., & WalumE. (1989). MEIC: a new international multicentre project to evaluate the relevance to human toxicity of in vitro cytotoxicity tests. Cell Biology and Toxicology5, 331–347.
23.
EkwallB., BondessonI., CastellJ.V., Gómez-LechónM.J., HellbergS., HögbergJ., JoverR., PonsodaX., RomertL., StenbergK., & WalumE. (1989). Cytotoxicity evaluation of the first ten MEIC chemicals: acute lethal toxicity in man predicted by cytotoxicity in five cellular assays and by oral LD50 tests in rodents. ATLA17, 83–100.
24.
StewartB.H., ChanO.H., JezykN., & FleisherD. (1997). Discrimination between drug candidates using models for evaluation of intestinal absorption. Advanced Drug Delivery Reviews23, 27–45.
25.
LeeC-P., de VruehR.L.A., & SmithP.L. (1997). Selection and development candidates based on in vitro permeability measurements. Advanced Drug Delivery Reviews23, 47–62.
26.
BehrensI., StenbergP., ArturssonP., & KisselT. (2001). Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-MTX cells. Pharmacological Research18, 1138–1145.
27.
StenbergP., LuthmanK., EllensH., LeeC.P., SmithP.L., LagoA., ElliottJ.D., & ArturssonP. (1999). Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical methods of increasing complexity. Pharmacological Research16, 1520–1526.
28.
StenbergP., NorinderU., LuthmanK., & ArturssonP. (2001). Experimental and computational screening models for the prediction of intestinal drug absorption. Journal of Medical Chemistry44, 1927–1937.
29.
GarbergP. (1998). In vitro models of the blood–brain barrier. ATLA26, 821–847.
30.
BasakS.C., GuteB.D., & DrewesL.R. (1996). Predicting blood–brain transport of drugs: a computational approach. Pharmacological Research13, 775–778.
31.
ClarkD.E. (1999). Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. II. Prediction of blood–brain barrier penetration. Journal of Pharmacological Science88, 815–821.
32.
OsterbergT., & NorinderU. (2001). Prediction of drug transport processes using simple parameters and PLS statistics. The use of ACD/logP and ACD/ChemSketch descriptors. European Journal of Pharmacological Science12, 327–337.
33.
GargasM.L., BurgessR.J., VoisardD.E., CasonG.H., & AndersenM.E. (1989). Partition coefficients of low-molecular weight volatile chemicals in various liquids and tissues. Toxicology and Applied Pharmacology98, 87–99.
34.
JepsonG.W., HooverD.K., BlackR.K., McCaffertJ.D., MahleD.A., & GearhartJ.M. (1994). A partition coefficient determination method for nonvolatile chemicals in biological tissue. Fundamental and Applied Toxicology22, 519–524.
35.
BlaauboerB.J., De JonghJ., ForsbyA., HeldringN., Nordin-AnderssonM., GuillouzoA., HoustonJ.B., WitherowL., OdlandL., BeckmanM., WalumE., CombesR., & ClothierR. (1998). An Integrated Approach to the Prediction of Systemic Toxicity Using Computer-based Biokinetic Models and Biological In Vitro Test Methods: a Prevalidation Study Based on the ECITTS Project. Report for the Environment Institute Joint Research Centre at Ispra.Ispra, VA, Italy: ECVAM.
36.
BlaauboerB.J., ForsbyA., HoustonJ.B., BeckmanM., CombesR.D., & De JonghJ. (2000). An integrated approach to the prediction of systemic toxicity by using biokinetic models and biological in vitro test methods. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 525–536. Amsterdam, The Netherlands: Elsevier.
37.
BjerregaardH.F., StærmoseS., & VangJ. (2001). Effect of linear alkylbenzene sulfonate (LAS) on ion transport and intracellular calcium in kidney distal epithelial cells (A6). Toxicology in Vitro15, 531–537.
JortaniS.A., & ValdesR. (1997). Digoxin and its related endogenous factors. Critical Reviews in Clinical Laboratory Science34, 225–274.
40.
ClaudioT. (1989). Molecular genetics of acetyl- choline receptor channels. In Frontiers in Molecular Neurobiology (ed. GloverD.M., & HamesB.D.), pp. 63–142. Oxford, UK: IRL Press.
41.
SaadW.A., CamargoL.A., GraeffF.G., Silva-NetoC.R., Antunes-RodriguesJ., & CovianM.R. (1976). The role of central muscarinic and nicotinic receptors in the regulations of sodium and potassium renal excretion. General Pharmacology7, 145–148.
42.
CampbellT.J., & WilliamsK.M. (2001). Therapeutic drug monitoring: antiarrhythmic drugs. British Journal of Clinical Pharmacology5, 21–33.
43.
SoubrieP., SimonP., & BoissierJ.R. (1976). Antagonism of diazepam against central anticholin-ergic drug-induced hyperactivity in mice: involvement of a GABA mechanism. Neuropharmacology15, 773–776.
44.
TusellJ.M., VendrellM., SerratosaJ., & TrullasR. (1992). Lindane-induced convulsions in NMRI and OF1 mice: antagonism with (+)MK-801 and voltage-dependent calcium channel blockers. Brain Research16, 209–214.
45.
NwanzeE., & JonssonG. (1981). Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice. Neuroscience Letters23, 163–168.
46.
BiedlerJ.L., Roffler-TarlovS., SchachnerM., & FreedmanL.S. (1978). Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Research38, 3751–3757.
47.
ForsbyA., PilliF., BianchiV., & WalumE. (1995). Determination of critical neurotoxic concentrations in human neuroblastoma (SH-SY5Y) cells. ATLA23, 800–811.
48.
VeronesiB., & ErichM. (1993). Differential cytotoxic sensitivity in mouse and human cell lines exposed to organophosphorus insecticides. Toxicology and Applied Pharmacology120, 240–246.
49.
FaurskovB., & BjerregaardH.F. (2000). Chloride secretion in kidney distal epithelial cells (A6) evoked by cadmium. Toxicology and Applied Toxicology163, 267–278.
50.
ErichM., CorrellL., & VeronesiB. (1997). Acetylcholinesterase and neuropathy target esterase inhibitions in neuroblastoma cells to distinguish organophosphorus compounds causing acute and delayed neurotoxicity. Fundamental and Applied Toxicology38, 55–63.
51.
VaughanP.F.T., PeersC., & WalkerJ.H. (1995). The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release. General Pharmacology26, 1191–1202.
52.
AndresM-I., ForsbyA., & WalumE. (1997). Polygodial-induced noradrenaline release in human neuroblastoma SH-SY5Y cells. Toxicology in Vitro11, 509–511.
53.
ScheersE.M., EkwallB., & DierickxP.J. (2001). In vitro long-term cytotoxicity testing 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data. Toxicology in Vitro15, 153–161.
54.
KolmanA., & ChovanecM. (2000). Combined effects of gamma-radiation and ethylene oxide in human diploid fibroblasts. Mutagenesis15, 99–104.
